IM1 Stock Overview
Implanet S.A., a medical technology company, manufactures and sells implants for orthopedic surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Implanet S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0015 |
| 52 Week High | €0.01 |
| 52 Week Low | €0.0005 |
| Beta | 1.08 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -1.7% |
| 1Y | n/a | -3.6% | 1.4% |
Return vs Industry: Insufficient data to determine how IM1 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how IM1 performed against the German Market.
Price Volatility
| IM1 volatility | |
|---|---|
| IM1 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IM1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IM1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 39 | Ludovic Lastennet | www.implanet.com |
Implanet S.A., together with its subsidiaries, researches and develops, manufactures, and sells spinal and orthopedic implants. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation.
Implanet S.A. Fundamentals Summary
| IM1 fundamental statistics | |
|---|---|
| Market cap | €5.61m |
| Earnings (TTM) | -€4.76m |
| Revenue (TTM) | €7.65m |
0.7x
P/S Ratio-1.2x
P/E RatioIs IM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM1 income statement (TTM) | |
|---|---|
| Revenue | €7.65m |
| Cost of Revenue | €3.90m |
| Gross Profit | €3.75m |
| Other Expenses | €8.51m |
| Earnings | -€4.76m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Mar 07, 2023
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 49.04% |
| Net Profit Margin | -62.16% |
| Debt/Equity Ratio | 292.2% |
How did IM1 perform over the long term?
See historical performance and comparison